Background: In 5%-10% of patients with of chronic myelogenous leukemia (CML), the Philadelphia chromosome (Ph) is not identified, despite the presence of the associated BCR-ABL molecular abnormality (Ph-negative, BCR-ABL-positive CML) because of sub-microscopic rearrangements.
Introduction
The balanced translocation t(9;22)(q34;qll), designated the Philadelphia chromosome (Ph), is found in 90%-95% of patients with chronic myelogenous leukemia (CML) [1, 2] . The 5BCR-ABL DNA on Ph is transcribed into an 8.5 kilobase (kb) chimeric BCR-ABL mRNA, which encodes a BCR-ABL protein of 210 kilodalton (KD). Thep210 protein has in vitro enhanced tyrosine kinase activity compared with the normal ABL protein [3] [4] [5] . Approximately 5%-10% of patients with a morphologic diagnosis of CML are Ph-negative [6] . They tend to be older (median age > 65 years), have monocytosis, thrombocytopenia, poor response to chemotherapy, and an overall shorter survival than patients with Ph-positive CML [7, 8] . Twenty-five to 30% of them show presence of the molecular BCR-ABL abnormality by Southern blot (Ph-negative BCR-ABL positive) and are indistinguishable from patients with Ph-positive CML in relation to characteristics, response and prognosis.
Recently we reported on the hypermetaphase fluorescence in situ hybridization (FISH) technique (HMF). It is a molecular-cytogenetic procedure which combines long-term (24-hour) mitotic arrest of bone marrow cultures, resulting in the capture of several hundred metaphases, with probes for analysis of Ph rearrangement by FISH [9] . By studying 70 double-blind samples from patients in different stages of Ph-positive CML, we identified Ph-positive cells in 16% (3 of 19) of patients characterized as having a complete cytogenetic response (Ph 0% by routine cytogenetic analysis) after interferon-a therapy. We also detected Ph-positive cells in one patient with an original diagnosis of Ph-negative, BCR-ABL positive CML. The latter observation stimulated interest in studying patients with this entity, hoping to understand better the disease biology.
Herein, we report the detailed cytogenetic and molecular analyses of six patients with Ph-negative, BCR-ABL positive CML. Using HMF, we were able to quantify the percentage of Ph-positive cells, and to identify differences in the involved structural changes.
Patients and methods

Samples
Bone marrow samples used in this study were obtained from six patients newly referred to our institution (patients 2 to 6) or already on therapy on our programs (patient 1) on protocols approved by The University of Texas, M.D. Anderson Cancer Center Surveillance Committee. Cytogenetic studies
The karyotype of leukemic cells was investigated using standard cytogenetic procedures. Metaphases were analyzed using Trypsin-Giemsa techniques [10] .
Southern blot analysis
Southern blot was performed as previously reported [11] . Briefly, high molecular weight DNA was extracted by DNA extractor (AB1, model 341, ABI, Foster City, CA). Genomic DNA was quantified by Du-7000 (Beckman) at O.D. 260 nm. DNA was digested with Bgl II and Xba I restriction enzymes, resolved on 0.8% agarose gel and transferred onto nylon membranes. Filters were hybridized with 32p-labeled UBCR probe (Oncogene Science Inc., Gaithersburg, MD). Filters were washed with 0.1 x SSC/0.1% SDS at 65 °C. Autography was for 48 hours. The autoradiographs were scanned and bands were quantified using Scan Analysis software from Biosoft (Cambridge. UK) and Macintosh-based scanner and computer.
Quantitative molecular analysis
After hybridization, Southern blots were scanned for 5-24 hours with a Betagen scanner (Betagen, Waltham, MA) that detects particle emissions and plots the origin of the particle to a location on the filter. Molecular weight and counts per minute of the rearranged and germline bands were determined as previously described [11] . The filters were mixed with ECL reagents and exposed to X-ray film for 1-10 minutes. The intensities o(p2I0 protein, and p!45 protein bands were scanned and a ratio of p210/pl45 proteins was obtained with a densitometer (Molecular Dynamics, Sunnyvale, CA) [12] .
HMF studies
Cells were cultured in T25 tissue culture flasks containing 10 ml of RPMI 1640 medium (GIBCO, Gaithersburg, MD) with 10% serum (GIBCO; newborn bovine serum: fetal bovine serum: 1:1). Cell densities were adjusted to not exceed 5 x 10 6 /ml, and incubation at 37 °C with 5% CO 2 for 24 hours was conducted. Cultures were then exposed to a concentration (0.1 ug/ml) of colcemid (N-methyl-N-deacetylcolchicine in phosphate-buffered saline (Boehringer, Mannheim) for 24 hours [9] .
Slide preparation and FISH
Cells were harvested, exposed to hypotonic treatment, fixed (methanol: acetic acid, 3:1), dropped onto slides, and FISH was conducted as has been previously reported by this laboratory [9] . Two different probes were used for FISH. Probe E6B was derived and prepared as previously described [13] by inter-Alu-PCR [14] from a radiation hybrid containing only approximately 5 Mb of human DNA from human chromosome band 9q34 as its only human genomic content allowing the ready detection of the portion of the ABL gene translocated to chromosome 22 to form the Ph chromosome as well as the portion left behind on chromosome 9. The second probe was prepared by interAlu-PCR from an interspecific somatic cell hybrid monochromo- 
Response to therapy
Complete hematologic remission (CHR) was defined as achievement of a WBC count below 10 x 10 9 /l with a normal differential, and no evidence of splenomegaly. Patients who attained normal blood counts but had a persistently abnormal differential or residual splenomegaly were classified as having a partial hematologic remission (PHR).
Results
The characteristics of the six patients at the time of HMF are detailed in Table 1 . All patients were in chronic phase CML and had the typical marrow morphological features. Their median age at the time of HMF was 43 years (range 31-54 years), and five were males. All patients except patient 6 had chromosomal studies at diagnosis which did not show the Ph abnormality. Repeat cytogenetic studies at referral to our center showed the same karyotype as at diagnosis in patients 1 to 5, and a normal karyotype in patient 6. Patients 2 to 6 were analyzed by HMF at the time of referral to MDACC simultaneous with the cytogenetic, Southern blot and 27O BCR-ABL p r o t e i n stuc jies ( Table 2) . Patient 1 was already a patient of our institution for eight years when studies were performed. All patients had evident BCR-ABL rearrangement by Southern blot (Figure 1 ). Four patients had active morphologic CML (patients 2, 3, 4 and 6) with elevated WBC counts, and two were in CHR. Three patients had been referred within six months of diagnosis (patients 3, 4, and 5); patients 2 and 6 were referred 26 and 222 months from diagnosis with active disease, while patient 1 was referred 91 months from diagnosis in CHR.
None of the six patients studied had evidence of a chromosome 9 or 22 abnormality by G-banding at diagnosis or at the time of HMF. Four patients had a normal karyotype, and two an abnormal karyotype (Table 2 ). In the two patients with chromosome aberrations, the abnormal clone was seen in more than 95% of metaphases. Southern blot analysis showed BCR rearrangement in all patients (Figure 1) .
Expression ofp210 protein was analyzed in patients 1, 2 and 5. In patient 2, p210 was expressed at very high levels (+4) (ratio: p210/pl45 = 4), but HMF showed only 5.2% Ph-positive cells. In the other two patients, p210 expression and HMF results correlated well with each other (patient 1: ratio ofp210/pl45 -0.5; patient 5: ratio o{p210/145 = 0.5). There were two patterns of Ph-positive detection by HMF. Four patients (1, 2, 5, 6) demonstrated a low frequency of t(9;22) Ph-positive cells (5.7%, 4.8%, 3.9%%, 0.2%, respectively) as typically seen in CML cells by HMF using an E6B probe [9] or by using chromosome 22 probe (Table 2) . Percentages reflect the mean between the results using the two different probes. The result using the E6B probe is demonstrated in cells from patient 6 in Figure 2 , panel A. In two patients (patients 3 and 4) the E6B probe detected an insertion of 9q34 material into chromosome 22 rather than a typical Ph translocation. This is shown for patients 3 and 4 in Figure 2 , panels B and C, respectively. Application of the chromosome 22 probe to these two samples, gave results consistent with that interpretation -two fluorescent staining bodies typical of chromosome 22 with no evidence of chromosome 22 material moved to any other chromosome (Figure 2, panel D) . The frequency of cells with the 9q34 insertion in patients 3 and 4 was high (74.2% and 92%, respectively).
Following the HMF, four patients (patients 1, 3, 4, 5) were treated with interferon-oc (IFN-a) regimens. Patient 3 received IFN-ot therapy for three months, then underwent allogeneic bone marrow transplantation. At the time of last follow-up, one patient (patient 2) had died in blastic phase 47 months from diagnosis; the remaining five patients were alive for periods of 16+-228+ months (median 52+ months). Four are in CHR or in chronic phase; the fifth (patient 3) is in CR post allogeneic transplant.
Discussion
At the molecular level, Ph-positive CML is characterized by BCR rearrangement and production of an enzymatically-enhanced p210 BCR-ABL [16] . Patients with CML lacking cytogenetic evidence of Ph may have subchromosomal molecular changes identical to those seen in Ph-positive patients. In Ph-negative CML, the finding of BCR-ABL molecular rearrangements indicated an undetected Ph translocation, and patients were grouped with, and treated as Ph-positive CML. The remaining patients who had Ph-negative, BCR-ABL-negative CML constitute a group with atypical morphologic and hematologic features, and with a relatively short survival [16] [17] [18] [19] [20] [21] , Their response to IFN-cx therapy is lower than in BCR-ABL-positive CML (33% versus 75%), but only a small number of patients have so far been treated.
The HMF procedure was effective in determining the frequency of Ph-positive cells in the bone marrow of CML patients undergoing treatment. Using HMF, in which 500 cells can be readily examined, a difference of 3.4% in the incidence of Ph-positive cells in marrows examined at two different time points could be statistically significant [9] . Therefore, HMF provides a precise estimate of small but significant changes in the frequency of Ph-positive cells in CML, which would be important for therapeutic decisions. This is the first report of the use of HMF in six patients with Ph-negative, BCR-ABL-positive CML. Two of the six patients showed an insertion of 9q34 into chromosome 22qll with a frequency of 74.2% and 92%. In both cases, the insertion was easily identified by HMF. In addition, HMF detected a low frequency of Ph-positive cells in four patients (patients 1, 2, 5 and 6). The pattern of UBCR was identical to the classical pattern in Ph-positive CML. The p210 results correlated well in two patients (patients 1 and 5), but were discordant in one (patient 2), in whom there was high p210 expression, but a low frequency of Ph-positive cells.
One important question is whether the remaining metaphases analyzed are leukemic or normal, since the HMF detected a low percentage of Ph-positive metaphases in patients 1, 2, 5 and 6 ( Table 2 ). Based on the high percent values of the rearranged bands compared with the germline bands (Figure 1 ; range 69%-88%), the most likely explanation is that most of the metaphases are leukemic, even though this is not confirmed by regular cytogenetic studies or by HMF. This may be because the amount of genetic material translocated or inserted to form the BCR-ABL abnormality is too subtle to be detected in most cells by these methods, but enough to produce the necessary molecular abnormality (BCR rearrangement, p210 BCR~ABh ) and consequent CML disease.
In summary, the HMF analysis was useful in identifying Ph-positive clones in all six patients with Ph-negative BCR-ABL-positive CML, and characterized the nature of the chromosome aberration, ie an insertion versus reciprocal translocation. It identified two distinct subsets of Ph-negative BCR-ABL-positive CML, one with an insertion of 9q34 into 22qll, and the other with a low frequency of typical Ph chromosome translocations. The use of HMF with other complementary molecular studies in larger study groups may help further define the heterogeneity and prognosis of Ph-negative BCR-ABL positive CML.
